{
    "clinical_study": {
        "@rank": "19988", 
        "arm_group": {
            "arm_group_label": "Nilotinib + Cetuximab", 
            "arm_group_type": "Experimental", 
            "description": "All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the recommended Phase II dose of nilotinib when\n      used in combination with cetuximab in the treatment of patients with recurrent and/or\n      metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck."
        }, 
        "brief_title": "A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colorectal Cancer", 
            "Head and Neck Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell\n             carcinoma of the head and neck\n\n          2. Previous therapy:\n\n               1. Patients must have progressed after standard therapy for metastatic/recurrent\n                  disease, including irinotecan and oxaliplatin-containing regimens for patients\n                  with CRC and platinum-containing regimens for patients with H&NSCC.\n\n               2. Patients may have received cetuximab or panitumumab previously\n\n          3. Ability to swallow medication tablets by mouth (which may include taking nilotinib\n             mixed in apple sauce)\n\n          4. At least one measurable lesion by RECIST criteria\n\n          5. A tumor lesion that can be readily biopsied using a core needle via clinical exam or\n             image-guidance.\n\n          6. Over the age of 18 years and able to provide informed consent\n\n          7. Adequate kidney, liver, and bone marrow function as follows:\n\n               1. Hemoglobin >/= 8.0 gm/dL\n\n               2. Absolute neutrophil count >/= 1500\n\n               3. Platelet count >/= 100,000\n\n               4. Creatinine within institutional normal limits or glomerular filtration rate > 60\n\n               5. Total bilirubin f.  AST and ALT\n\n          8. Life expectancy of greater than 3 months\n\n          9. ECOG performance status\n\n         10. Normal left ventricular ejection fraction, defined as EF > 50%\n\n        Exclusion Criteria:\n\n          1. Chemotherapy or surgery within 4 weeks prior to treatment start\n\n          2. Radiation treatment within 3 weeks prior to treatment start\n\n          3. Prior therapy with nilotinib, ponatinib, dasatinib, or imatinib\n\n          4. Untreated brain metastases or neurologically unstable central nervous system\n             metastases; CNS metastases will be considered stable if there is no new nor enlarging\n             lesions for one month, and the patient remains off steroids and anti-epileptics for\n             the same time period\n\n          5. Any severe or uncontrolled medical condition or other condition that could affect\n             participation in this study, including: unstable angina, uncontrolled hypertension,\n             serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial\n             infarction\n\n          6. Diarrhea > Grade 1 at baseline\n\n          7. Concomitant medication or herbal therapy known to inhibit CYP3A4\n\n          8. Gastrointestinal tract disease resulting in the inability to take oral medication or\n             a requirement for IV alimentation, prior surgical procedures affecting absorption, or\n             active peptic ulcer disease\n\n          9. Ongoing ventricular cardiac dysrhythmias of NCI CTCAE grade >/= 2\n\n         10. Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia or\n             ventricular fibrillation >/= 3 beats in a row)\n\n         11. Serious cardiac arrhythmia requiring medication\n\n         12. QTc interval > 500 msec\n\n         13. Female patients who are pregnant or breast feeding, or adults who are of reproductive\n             potential and are unwilling to refrain from conceiving a child during study treatment\n\n         14. Patients unwilling or unable to comply with the protocol, or provide informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01871311", 
            "org_study_id": "2013-0039"
        }, 
        "intervention": {
            "arm_group_label": "Nilotinib + Cetuximab", 
            "description": "Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly\nThree dose levels for nilotinib:\nDose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID\nCycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity.", 
            "intervention_name": "Nilotinib + Cetuximab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cetuximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "metastatic Kras wildtype", 
            "squamous cell carcinoma", 
            "cetuximab", 
            "nilotinib"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "leyl@georgetown.edu", 
                "last_name": "Lisa Ley, RN", 
                "phone": "202-687-6653"
            }, 
            "contact_backup": {
                "email": "brandon.g.smaglo@gunet.georgetown.edu", 
                "last_name": "Brandon Smaglo, MD", 
                "phone": "202-444-1781"
            }, 
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20007"
                }, 
                "name": "Georgetown Lombardi Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Brandon Smaglo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab", 
        "overall_contact": {
            "email": "leyl@georgetown.edu", 
            "last_name": "Lisa Ley, RN", 
            "phone": "202-687-6653"
        }, 
        "overall_contact_backup": {
            "email": "brandon.g.smaglo@gunet.georgetown.edu", 
            "last_name": "Brandon Smaglo, MD", 
            "phone": "202-444-1781"
        }, 
        "overall_official": {
            "affiliation": "Georgetown University", 
            "last_name": "Brandon Smaglo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The dose at which </= 1 out of 6 subjects experiences a dose limiting toxicity", 
            "measure": "Maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01871311"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Georgetown University", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Georgetown University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}